954 related items for PubMed ID: 9450921
1. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI.
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[Abstract] [Full Text] [Related]
2. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O.
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[Abstract] [Full Text] [Related]
3. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[Abstract] [Full Text] [Related]
4. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
5. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R, Klarnet J, Zuckerman N, Harrer G, McCloskey R, Gersh R, Goldberg R, Nichols W, Jacobs A, Weiden P, Montgomery P, Rivkin S, Appelbaum FR, Bensinger WI.
Bone Marrow Transplant; 1998 Oct; 22(7):651-9. PubMed ID: 9818692
[Abstract] [Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB.
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[Abstract] [Full Text] [Related]
7. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[Abstract] [Full Text] [Related]
8. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[Abstract] [Full Text] [Related]
9. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[Abstract] [Full Text] [Related]
10. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[Abstract] [Full Text] [Related]
11. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[Abstract] [Full Text] [Related]
12. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA, Weaver CH, Demirer T, Sanders JE, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Maziarz R, Klarnet JP, Rivkin S, Trueblood K, Storb R, Holmberg L, Buckner CD.
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[Abstract] [Full Text] [Related]
13. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[Abstract] [Full Text] [Related]
14. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H.
Cancer; 1996 Jun 01; 77(11):2302-7. PubMed ID: 8635099
[Abstract] [Full Text] [Related]
15. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
Bone Marrow Transplant; 1993 Oct 01; 12(4):337-45. PubMed ID: 7506091
[Abstract] [Full Text] [Related]
16. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
Bone Marrow Transplant; 1999 Sep 01; 24(5):473-81. PubMed ID: 10482930
[Abstract] [Full Text] [Related]
17. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R, Maloney D, Chauncey T, Appelbaum F, Bensinger W.
Bone Marrow Transplant; 2003 Aug 01; 32(3):279-85. PubMed ID: 12858199
[Abstract] [Full Text] [Related]
18. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
Biol Blood Marrow Transplant; 2005 Sep 01; 11(9):688-97. PubMed ID: 16125639
[Abstract] [Full Text] [Related]
19. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Fermé C, Gisselbrecht C.
Bone Marrow Transplant; 1999 Oct 01; 24(7):747-55. PubMed ID: 10516678
[Abstract] [Full Text] [Related]
20. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
Bone Marrow Transplant; 2002 Dec 01; 30(12):885-91. PubMed ID: 12476281
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
